A Phase III Study Comparing the Side Effects of Proton Beam Therapy and Intensity-Modulated Radiation Therapy in Men with Localized Prostate Cancer

Full Title

Prostate Advanced Radiation Technologies Investigating Quality of Life: A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer

Purpose

Proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT) are both used to treat prostate cancer that has not grown outside the prostate gland. PBT uses protons to target and kill cancer cells, while IMRT uses custom-shaped x-ray beams.

Both are highly precise radiation treatments that aim to target just the tumor while sparing as much nearby healthy tissue as possible. However, there is a risk of side effects with both therapies, including bowel, urinary, and erectile problems. While both therapies have been widely used to treat prostate cancer, there has never been a study to compare the side effects of these two different treatments. That is the goal of this study.

Patients in this study will be randomly assigned to receive either IMRT or PBT. They'll be asked to complete questionnaires about their quality of life so researchers can compare the side effects of these radiation treatments.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have localized prostate cancer and be planning to receive radiation therapy.
  • Patients may not have received prior treatment for their prostate cancer.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for men age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Oren Cahlon at 212-639-5219.

Protocol

15-205

Phase

III

Disease Status

Newly Diagnosed

Investigator

Co-Investigators